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Abstract 21 
Background: Periconceptional folic acid prevents neural tube defects (NTD), but it is uncertain 22 
whether there are benefits for offspring neurodevelopment arising from continued maternal folic acid 23 
supplementation beyond the first trimester. We investigated the effect of folic acid supplementation 24 
during trimesters 2 and 3 of pregnancy on cognitive performance in the child. 25 
Methods: We followed up the children of mothers who had participated in a randomized controlled 26 
trial in 2006/2007 of Folic Acid Supplementation during the Second and Third Trimesters (FASSTT) 27 
and received 400µg/d folic acid or placebo from the 14th gestational week until the end of pregnancy. 28 
Cognitive performance of children at 7 years was evaluated using the Wechsler Preschool and Primary 29 
Scale of Intelligence (WPPSI-III) and at 3 years using the Bayley’s Scale of Infant and Toddler 30 
Development (BSITD-III). 31 
Results: From a total of 119 potential mother-child pairs, 70 children completed the assessment at age 32 
7 years, and 39 at age 3 years.  At 7 years, the children of folic acid treated mothers scored significantly 33 
higher than the placebo group in word reasoning: mean 13.3 (95% CI 12.4-14.2) versus 11.9 (95% CI 34 
11.0-12.8); p=0.027; at 3 years they scored significantly higher in cognition: 10.3 (95% CI 9.3-11.3) 35 
versus 9.5 (95% CI 8.8-10.2); p=0.040. At both time points, greater proportions of children from folic 36 
acid treated mothers compared with placebo had cognitive scores above the median values of 10 (girls 37 
and boys) for the BSITD-III, and 24.5 (girls) and 21.5 (boys) for the WPPSI-III, tests. When compared 38 
with a nationally representative sample of British children at 7 years, WPPSI-III test scores were higher 39 
in children from folic acid treated mothers for verbal IQ (p<0.001), performance IQ (p=0.035), general 40 
language (p=0.002) and full scale IQ (p=0.001), whereas comparison of the placebo group with British 41 
children showed smaller differences in scores for verbal IQ (p=0.034) and full scale IQ (p=0.017) and 42 
no differences for performance IQ or general language. 43 
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Conclusions: Continued folic acid supplementation in pregnancy beyond the early period 44 
recommended to prevent NTD may have beneficial effects on child cognitive development.  Further 45 
randomized trials in pregnancy with follow-up in childhood are warranted.  46 
Trial registration: ISRCTN ISRCTN19917787. Registered 15 May 2013. 47 
Keywords: Prenatal folic acid, Pregnancy, Cognitive performance, Child, Randomized controlled 48 
trial, Public health, Wechsler Preschool and Primary Scale of Intelligence 49 
 50 
Background 51 
Folate plays a crucial role in pregnancy and fetal development as it is essential for cell division and 52 
tissue growth, by acting as the key co-factor in one-carbon metabolism and therefore required for 53 
nucleotide biosynthesis, amino acid metabolism and numerous methylation reactions [1].  Conclusive 54 
scientific evidence has existed for over 25 years that periconceptional folic acid (FA; the synthetic 55 
vitamin form) can protect against neural tube defects (NTDs) [2, 3], but apart from the early pregnancy 56 
period targeted for preventing NTD, maternal folate may have other roles in offspring health and 57 
particularly in relation to neurodevelopment in the child [4–9].  Folate is recognized among key 58 
nutrients required for the formation and development of fetal brain [10] owing to its involvement in 59 
the proliferation and growth of neuronal cells and the synthesis of neurotransmitters [11]. Experimental 60 
evidence from in vivo studies shows that there is active placental transport of folate and elevated total 61 
folate concentrations are found in the brain during early fetal development [12, 13], while prenatal 62 
folate deficiency was shown in animal models to decrease progenitor cell proliferation, increase 63 
apoptosis and provoke structural changes in the brain [14, 15].  Observational studies in humans have 64 
linked self-reported FA supplement use in the first trimester of pregnancy with better cognitive 65 
performance [6–9] and specifically with improved vocabulary and verbal skills [8] in children. Of 66 
particular note, one large study of almost 40,000 children in the US found a lower rate of severe 67 
language delay in children at 3 years whose mothers reported taking FA in the first trimester of 68 
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pregnancy [7]. Maternal FA supplement use was also associated with lower risk of child behavioral 69 
and emotional problems [16, 17]. One study however, found no evidence in secondary analysis that 70 
maternal FA supplementation up to the 8th gestational week was associated with long-term somatic 71 
and mental development in children [18], albeit this was designed to investigate the effect of 72 
multivitamin supplementation on NTD risk and therefore focused on very early pregnancy only, 73 
possibly explaining the lack of relationship of FA use with child cognition. 74 
Later pregnancy (i.e. 24-42 gestational weeks) is recognized to be a crucial period for brain 75 
growth [19], but far fewer human studies have examined maternal folate status at this time in relation 76 
to subsequent cognitive performance in childhood.  One study over 40 years ago however reported that 77 
children born to mothers with a diagnosis of folate-related megaloblastic anemia during the third 78 
trimester of pregnancy had abnormal neurodevelopment and lower intellectual abilities compared with 79 
infants born to mothers with optimal folate status [4]. Much more recently, a longitudinal study of 256 80 
mother-child pairs linked maternal folate deficiency diagnosed at the start of the second trimester with 81 
reduced brain volume in the children at 6-8 years, as measured using magnetic resonance imaging 82 
(MRI) [20]. Correspondingly, higher plasma folate concentrations during at the 30th gestational week 83 
were associated with better cognitive performance in over 500 children in South India sampled at aged 84 
9-10 years [5]. However, the evidence is not entirely consistent, with two longitudinal observational 85 
studies from Canada and the US, respectively, reporting no significant associations of maternal folate 86 
biomarkers sampled at several time-points between the 16th and the 37th gestational weeks with infant 87 
neurodevelopment [21] or cognitive performance of children at age 5 years [19]. 88 
Although the totality of evidence generally supports an association of maternal folate during 89 
pregnancy with neurodevelopment and cognitive performance in the first decade of life, it is not clear 90 
if this relationship is causative as the evidence is drawn from observational studies, often relying on 91 
FA supplement use in pregnancy as reported by the mother; information typically collected 92 
retrospectively (at time of assessing the child) and thus with a high risk of recall bias. Therefore, it is 93 
uncertain whether there are any benefits for the offspring brain arising from continued maternal folic 94 
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supplementation beyond the first trimester. Accordingly, we conducted a follow-up study of children 95 
whose mothers had participated in a randomized controlled trial (RCT) of FA during trimesters 2 and 96 
3 of pregnancy to investigate the effect of maternal FA supplementation on the subsequent cognitive 97 
performance in the child. 98 
 99 
Methods 100 
Study population  101 
This was a follow-up investigation of children whose mothers took part in the Folic Acid 102 
Supplementation during the Second and Third Trimesters (FASSTT) trial in pregnancy. The original 103 
FASSTT trial conducted in 2006/2007 has been described in detail elsewhere [22]. Briefly for the 104 
purpose of this report, healthy pregnant women, aged 18-35 years with a singleton pregnancy and who 105 
had taken the recommended dose of 400µg/d of FA in the first trimester, were recruited from antenatal 106 
clinics at the 14th week of gestation (Fig 1). At the start of the second trimester, eligible participants 107 
were randomly assigned to take 400µg/d FA or placebo for 26 weeks, of which 59 women in the 108 
treatment group and 60 in the placebo group completed the trial.  FA supplements were distributed (in 109 
7-day pillboxes) to participants every 4 weeks. Based on the recording of unused tablets, an overall 110 
participant compliance rate of 93% was estimated.  111 
The FASSTT Offspring Trial was approved by the Office for Research Ethics Committees 112 
Northern Ireland and was registered (ISRCTN19917787). Participants from the original FASSTT trial 113 
were sent an invitation letter, and in a follow-up telephone call, those who verbally consented to take 114 
part were given an appointment to attend the Nutrition Innovation Centre for Food and Health at Ulster 115 
University.  In compliance with ethical requirements, signed written consent from the mother and 116 
assent from the child were obtained at the time of the appointment. All efforts were made to recruit 117 
the maximum number of participants from the original FASSTT trial. If current contact details were 118 
not readily available from our records, the new participant details were traced through health records. 119 
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Those who failed to attend their appointment were offered an alternative date (up to a maximum of 5 120 
appointments).  121 
Fig. 1 Flowchart showing the study population. 122 
 123 
Measurements of the FASSTT Offspring trial 124 
Cognitive tests  125 
Cognitive performance of the children at age 7 years was completed by a trained researcher using the 126 
Wechsler Preschool and Primary Scale of Intelligence test 3rd UK edition (WPPSI-III). This validated 127 
clinical instrument for assessing children (up to age 7 years and 3 months) provides composite scores 128 
representing intellectual functioning in specified cognitive domains (i.e. Verbal IQ, Performance IQ 129 
and Processing Speed) and an overall score for Full Scale IQ. Each assessment lasted 40-50 minutes 130 
and was completed by the same researcher in one session. To provide an appropriate environment for 131 
assessing the child, the room was well-lit, ventilated and free from distractions, with the researcher 132 
seated directly opposite the child and the mother outside of the child’s view. Both researcher and 133 
participants were blinded to treatment allocations in the original FASSTT trial. 134 
Prior to conducting the main assessment of the children at 7 years, a pilot investigation of 135 
participants at 3 years was conducted using the Bayley’s Scales of Infant and Toddler Development 136 
3rd Edition (BSITD-III), the most frequently used developmental test for infants and young children of 137 
1-42 months, which includes an assessment of cognitive performance, along with other developmental 138 
domains such as receptive and expressive communication, and fine and gross motor skills.  139 
 140 
Anthropometric measurements of the child 141 
Height, weight, waist and head circumference and body fatness were measured using standardized 142 
equipment on the day of the appointment. Height (cm) was measured using a portable, standalone 143 
stadiometer, with shoes removed. Weight (kg) was measured to the nearest 0.1kg using electronic 144 
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weighing scales, with any heavy clothing removed. Waist and head circumference (cm) were measured 145 
using a non-elastic measuring tape. Body Mass Index (BMI) was calculated as weight in 146 
kilograms/height in meters squared. Z-scores for BMI were calculated based on the Centre for Disease 147 
Control Growth Charts and using the LMS method, which involves the equation Z= ((BMI/M)^L-148 
1)/(LxS) [23]. The parameters of the formula include, M, the median BMI by age, S corresponds to 149 
the coefficient of variation of BMI, and the L allows for age dependent skewness in the distribution of 150 
body mass index [24]. For children aged 7 years, body fat measures were also obtained using the 151 
Tanita-305 body fat analyzer (Tanita Corp, Tokyo, Japan). 152 
 153 
Laboratory assessment 154 
Non-fasting blood samples, collected from the mother at 14th and 36th  gestational weeks and umbilical 155 
cord blood at delivery, were analyzed for serum and red blood cell (RBC) folate by microbiological 156 
assay [25]. Methylenetetrahydrofolate reductase (MTHFR) C677T genotype was identified using 157 
polymerase chain reaction amplification, followed by HinfI digestion [26]. 158 
 159 
Statistical analyses 160 
Estimation of the sample size for the current study was based on our pilot investigation in 39 children 161 
sampled at 3 years, where assessment scores for the cognitive domain in the BSITD-III test from 162 
children of mothers supplemented with folic acid or placebo were used. A sample size of 43 children 163 
in each group was estimated for the assessment at 7 years to detect a significant difference in cognitive 164 
performance between children of the mothers randomized to each treatment with a power of 80% at 165 
α=0.05 [27].  166 
Statistical analysis was performed using the Statistical Package for the Social Sciences software 167 
(version 21.0; SPSS UK Ltd. Chertsey, UK).  For normalization purposes, variables were log 168 
transformed before analysis, as appropriate. Differences between placebo and treatment groups were 169 
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analyzed using independent t-tests for linear variables and chi square tests for categorical variables. 170 
Raw cognitive scores were standardized for the child’s age at time of testing and appropriate age-171 
specific reference intervals were applied in adherence with test protocols. Analysis of covariance 172 
(ANCOVA) was used to test for differences in cognitive variables between treatment groups, with 173 
adjustment for relevant confounding factors, including maternal age and education attainment [28], 174 
child’s sex [29, 30], birth weight [31] and breastfeeding [28]. Multiple linear regression analysis was 175 
used to examine the predictors of cognitive performance in children at 7 years. Further analysis 176 
compared mean WPSSI-III composite tests scores for FASSTT Offspring trial participants with test 177 
scores from a nationally representative sample of British children using a one-sample t-test.  The latter 178 
cohort, collected for the UK WPPSI-III Project, was specifically sampled to validate this test for use 179 
in the UK. During 2002-2003, children were sampled to represent the UK population according to the 180 
2001 Census, in terms of geographic regions, sex, age, ethnicity and parental educational level [32]. 181 
Of a total of 805 children of age 2 years 6 months to 7 years 3 months sampled for this validation 182 
project, the mean WPSSI-III scores for 41 children at age 7 years were used in the current analysis.  183 
 184 
Results 185 
Of 119 participants in the original FASSTT trial, 70 mother-child pairs completed the FASSTT 186 
Offspring Trial at 7 years, representing a 59% response rate. Of the 70 children sampled, 50% (n= 34) 187 
was previously also sampled for the pilot study at 3 years, along with 5 other children who were not 188 
available for the 7 year follow-up (providing a total of 39 children for assessment at 3 years). A 189 
comparison of responders and non-responders to follow-up at 7 years showed no significant 190 
differences in any general characteristic, including maternal age (P = 0.207), weeks of gestation at 191 
labor (P = 0.587), parity (P = 0.198), birth weight (P = 0.642), Apgar score at 5th minute (P = 0.760) 192 
or % breast fed from birth (P = 0.415). Likewise, there were no significant differences in general 193 
characteristics between treatment groups among non-responders (Additional File 1: Table S1).  No 194 
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adverse events were reported at any time during the FASSTT trial or at either of the follow-up phases 195 
of the study. 196 
 197 
Study cohort characteristics and folate biomarkers in mothers and newborns 198 
There were no significant differences between the placebo and treatment groups in general maternal 199 
or child characteristics (Table 1 and Additional File 1: Table S2).  Pre-intervention (i.e. at the 14th 200 
gestational week), neither serum nor RBC folate showed significant differences between the treatment 201 
groups, but both biomarkers were significantly higher in the FA group compared with placebo 202 
following intervention (Table 2). Analysis of the cord blood at delivery also showed significantly 203 
higher folate concentrations in the FA treatment group. The frequency of the MTHFR 677TT genotype 204 
(variant genotype for a common folate polymorphism) was not significantly different between the 205 
treatment groups among mothers or children. 206 
 207 
Table 1 General characteristics of FASSTT Offspring trial participants at age 3 and 7 years 208 
 Participants at 3 years (n = 39)  Participants at 7 years (n = 70) 
 Placebo (n = 16) Folic acid (n = 23)  Placebo (n = 33) Folic acid (n = 37) 
Maternal Characteristics      
Age, yearsa 27.1 (25.1, 29.0) 28.8 (27.2, 30.4)  28.0 (26.4, 29.6) 29.4 (28.2, 30.7) 
BMI, kg/m2 25.0 (22.9, 27.1) 25.7 (22.8, 28.6)  24.3 (23.1, 25.6) 25.3 (23.5, 27.2) 
Smoking in pregnancy, % 38 22  12 19 
Alcohol use, % 6 0  3 3 
Duration of folic acid use at 
time of enrolment, weeks 
13.5 (8.4, 18.6) 12.0 (9.0, 15.0)  13.6 (10.7, 16.4) 12.8 (10.5, 15.1) 
Iron supplement use, % 25 22  18 27 
Married, % 73 91  88 95 
Education attainment, yearsb 19.2 (17.8, 20.6) 19.7 (18.5, 20.9)  19.6 (18.5, 20.6) 19.5 (18.5, 20.4) 
Homeowner, % 60 76  79 76 
Parity (n) 2.9 (2.5, 3.3) 3.2 (2.7, 3.6)  2.6 (2.3, 2.9) 2.8 (2.5, 3.1) 
Week of gestation at labor 40.0 (39.3, 40.7) 40.0 (39.3, 40.6)  40.2 (40.0, 40.7) 39.9 (3.94, 40.3) 
Child Characteristics at birth      
Sex, Female % 75 65  48 59 
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Birth weight, g 3392 (3144,3640) 3317 (3029,3605)  3519 (3323,3716) 3374 (3188,3559) 
Birth length, cm 51.1 (49.9, 52.4) 50.6 (49.6, 51.7)  51.4 (50.4, 52.4) 50.8 (50.1, 51.5) 
Head circumference, cm 34.4 (33.6, 35.2) 34.4 (33.6, 35.2)  34.6 (34.1, 35.2) 34.6 (34.1, 35.1) 
Apgar at 1st minute 8.3 (7.6, 8.9) 8.5 (8.2, 8.8)  8.5 (8.1, 8.9) 8.7 (8.5, 8.8) 
Apgar at 5th minute 9.0 (9.0, 9.0) 9.0 (8.9, 9.1)  9.0 (8.8, 9.1) 9.0 (8.9, 9.1) 
Breastfed from birth, % 56 44  39 46 
Child Characteristics at follow-up      
Age at assessment, years 2.8 (2.5, 3.0) 2.7 (2.6, 2.9)  6.8 (6.7, 6.9) 6.7 (6.7, 6.8) 
BMI Z-scorec 0.55 (-0.39, 1.48) 0.19 (-0.19, 0.57)  0.24 (-0.11, 0.58) -0.08 (-0.40, 0.23) 
Continuous measures presented as mean (95% CI), unless otherwise indicated. Categorical measures compared using 209 
Pearson’s chi-square, as appropriate.   210 
aRefers to age of mother at enrolment to the FASSTT trial 211 
 bAge of leaving of formal education 212 
cBody Mass Index (BMI) was calculated as weight in kilograms/height in meters squared.  BMI Z-score was calculated 213 
based on the Centre for Disease Control Growth Charts and using the LMS method, using the equation Z= (BMI/M)^L-214 
1)/(LxS)[23]. The parameters of the formula include: M the median BMI by age; S corresponding to the coefficient of 215 
variation of BMI; and L which allows for age-dependent skewness in the distribution of body mass index[24].  216 
 217 
 218 
Table 2 Maternal and cord blood folate biomarkers of FASSTT trial participants 219 
 Placebo (n = 33) Folic acid (n = 37) p value 
14th GW (pre-intervention)    
Serum folate, nmol/L 48.7 (40.7, 56.7) 45.6 (39.1, 52.1) 0.544 
RBC folate, nmol/L 1109 (846, 1371) 1223 (1025, 1421) 0.312 
36th GW (post-intervention)a    
Serum folate, nmol/L 26.0 (18.9, 33.2) 51.1 (43.6, 58.6) <0.001 
RBC folate, nmol/L 978 (823, 1133) 1834 (1609, 2060) <0.001 
MTHFR 677TT genotype, % 9 16 0.595 
Cord bloodb    
Serum folate, nmol/L 71.7 (60.5, 83.0) 99.1 (86.6, 111.6) 0.002 
RBC folate, nmol/L 1535 (1260, 1810) 2177 (1779, 2574) 0.009 
MTHFR 677TT genotype, % 14 9 0.914 
Continuous measures presented as mean (95% CI) unless otherwise indicated. Continuous measures 220 
compared using independent samples t-test. Count measures compared using Pearson’s chi-square.  221 
aPost-intervention, following supplementation with folic acid (400µg/d) for 22 weeks in pregnancy  222 
bCord blood collected upon delivery 223 
 224 
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Effect of maternal folic acid during pregnancy on offspring cognition 225 
WPPSI-III composite test scores from children at age 7 years are presented in Table 3. Following 226 
adjustment for child’s sex, birth weight, breastfeeding, maternal age and maternal education 227 
attainment, analysis showed that children born to mothers who had received FA in pregnancy scored 228 
significantly higher in word reasoning compared to children from the placebo group [mean (95% CI)]: 229 
13.3 (12.4-14.2) vs 11.9 (11.0-12.8), P=0.027.  No other statistically significant differences in WPPSI-230 
III scores were observed between the two groups (results of all subtests are provided in Additional 231 
File 1: Table S3).   232 
 233 
Table 3 WPPSI-III test scores of FASSTT Offspring trial participants at 7 yearsa 234 
Composite  
and subtest scores 
Placebo (n = 33) Folic acid (n = 37) Difference 
p value 
(unadjusted)b 
p value 
(adjusted)c 
Verbal IQ  103.4 (99.4, 107.4) 107.7 (103.7, 111.8) 4.3 (-1.2, 9.9) 0.126 0.120 
Information 10.9 (9.9, 11.8) 11.1 (10.3, 12.0) 0.3 (-1.0, 1.5) 0.648 0.630 
Vocabulary 9.6 (8.9, 10.4) 10.3 (9.5, 11.1) 0.7 (-0.4, 1.8) 0.221 0.262 
Word Reasoning 11.9 (11.0, 12.8) 13.3 (12.4, 14.2) 1.4 (0.2, 2.6) 0.023 0.027 
Performance IQ 100.6 (96.5, 104.6) 104.1 (99.1, 109.1) 3.5 (-2.9, 9.8) 0.274 0.429 
Processing Speed 103.9 (98.1, 109.7) 102.5 (97.4, 107.7) 1.4 (-6.2, 8.9) 0.718 0.712 
General Language 105.8 (101.1, 110.5) 108.9 (104.5, 113.2) 3.1 (-3.2, 9.4) 0.334 0.514 
Full Scale IQ 103.5 (99.3, 107.6) 106.4 (101.7, 111.1) 3.0 (-3.3, 9.2) 0.348 0.441 
Data presented as mean (95% CI).   235 
aTest scores assessed by Wechsler Preschool and Primary Scale of Intelligence test, 3rd UK edition (WPPSI-III).  236 
Data analyzed by bindependent t-test and cANCOVA, with adjustment for maternal age and education attainment 237 
[28], child’s sex [29, 30], birth weight [31] and breastfeeding [28]. Results considered significant when P < 238 
0.05. 239 
 240 
When compared with a nationally representative sample of British children at age 7 years, 241 
WPPSI-III scores were found to be higher in children from FA treated mothers for verbal IQ (107.7 vs 242 
99.1, P<0.001), performance IQ (104.1 vs 98.7, P=0.035), general language (108.9 vs 101.8, P=0.002) 243 
and full scale IQ (106.4 vs 98.3, P=0.001) (Table 4).  Comparison of the placebo group with British 244 
children however showed smaller differences in scores for verbal IQ (103.4 vs 99.1, P=0.034) and full 245 
scale IQ (103.5 vs 98.3, P=0.017) and no differences in performance IQ or general language scores. 246 
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In neither the FA nor the placebo group were scores for processing speed found to be different from 247 
the UK mean scores for children of this age.  248 
 249 
Table 4 Comparison between WPPSI-III test scores of FASSTT Offspring trial participants with a 250 
representative sample of British children  251 
Composite scores UK Mean (n=41) Placebo (=33) p value Folic acid (n=37) p value 
Verbal IQ 99.07 103.4 0.034 107.7 <0.001 
Performance IQ 98.74 100.6 0.361 104.1 0.035 
Processing Speed 101.32 103.9 0.373 102.5 0.636 
General Language 101.85 105.8 0.098 108.9 0.002 
Full Scale IQ 98.31 103.5 0.017 106.4 0.001 
Data presented as mean. P values refer to data analyzed by a one-sample t-test for comparison of placebo and 252 
treatment groups with WPPSI-III test scores from a representative sample of British children [32]. Results 253 
considered significant when p<0.05. 254 
 255 
Maternal biomarker status of folate at the 36th gestational week was found to be a significant 256 
predictor of subsequent verbal IQ (but not other WPPSI-III scores) in children at 7 years: β = 0.268 257 
(95% CI 0.000-0.001) P = 0.027 for serum folate, after adjustment for relevant covariates, namely 258 
maternal age [28], maternal education attainment [28], child’s sex [29, 30] and breastfeeding [28] 259 
using multiple linear regression analysis (Additional File 1: Table S4). In this analysis, apart from 260 
maternal folate status at the 36th gestational week, breastfeeding was the only factor significantly 261 
related to child cognition as determined by WPPSI-III test scores for verbal IQ: β = 0.300 (95% CI 262 
0.005-0.053) P = 0.017;  general language: β = 0.369 (95% CI 3.387-16.142) P = 0.003; and full scale 263 
IQ: β = 0.314 (95% CI 1.622-14.837) P = 0.016.  264 
In the sample of children assessed also at age 3 years, those whose mothers received FA 265 
treatment during pregnancy scored significantly higher in the cognitive domain of the BSITD-III test 266 
compared to children from placebo mothers (Table 5).  No significant differences between the 267 
treatment groups in any other developmental domain of the BSITD test were observed. 268 
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In both assessments- (performed at 3 and 7 years), greater proportions of girls and boys from 269 
folic acid treated mothers compared with placebo had cognitive scores above the median value of 10 270 
(girls and boys) for the BSITD-III, and 24.5 (girls) and 21.5 (boys) for WPPSI-III (Fig 2).  271 
 272 
Table 5 Developmental scores of FASSTT Offspring trial participants at 3 yearsa 273 
Developmental Domains Placebo (n = 16) Folic acid (n = 23) Difference 
p value 
(unadjusted)b 
p value 
(adjusted)c 
Cognitiveb 9.5 (8.8, 10.2) 10.3 (9.3, 11.3) 0.8 (-0.5, 2.1) 0.223 0.040 
Receptive communication 10.3 (9.0, 11.5) 10.5 (9.4, 11.6) 0.2 (-1.4, 1.8) 0.775 0.395 
Expressive communication 11.3 (10.0, 12.5) 10.3 (9.1, 11.5) 1.0 (-0.7, 2.7) 0.257 0.634  
Fine motor 9.8 (8.9, 10.7) 10.4 (9.1, 11.6) 0.5 (-1.1, 2.2) 0.515 0.302 
Gross motor 8.6 (7.5, 9.6) 8.6 (7.7, 9.4) 0.0 (-1.3, 1.3) 0.997 0.828 
Data presented as mean (95% CI).  274 
aDevelopmental scores assessed by the BSITD-III.  275 
Data analyzed by bindependent t-test and cANCOVA, adjusting for maternal age and education attainment [28], and 276 
child’s birth weight [31]. Results considered significant when p < 0.05. 277 
 278 
 279 
Fig. 2 Percentage of FASSTT Offspring participants at 3 and 7 years achieving above average cognitive 280 
performance. In children at 3 years, cognitive performance was assessed by the BSITD-III test and at 281 
7 years by the WPPSI-III test. Values are shown as % of children at 3 or 7 years, by treatment group 282 
of the mother, who achieved above the median cognitive score for same-sex children at that age versus 283 
those who scored at and below the median scores of 10 (for girls and boys) in the BSITD-III test; 24.5 284 
(for girls) and 21.5 (for boys) in the WPPSI-III test. Total numbers at each age and sex group are: girls 285 
at 3 years, n=27; boys at 3 years, n=12; girls at 7 years, n=38; boys at 7 years, n=32. 286 
 287 
Discussion 288 
As a follow-up study of children whose mothers had participated in an RCT during trimesters 2 and 3 289 
of pregnancy, the FASSTT Offspring study provides the first randomized trial evidence that continuing 290 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
4 
5 
6 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
3  
39 
40 
41 
42 
43 
44 
45 
46 
47 
4  
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
FA supplementation throughout pregnancy, well beyond the early period known to be protective 291 
against NTDs, can influence cognitive development of the child up to 7 years of age.  Using validated 292 
and internationally recognized tools to measure cognitive performance in children, we show that the 293 
children of FA treated mothers during pregnancy had a higher score in the cognitive domain of 294 
developmental assessment at 3 years and in word reasoning testing at 7 years. When compared with a 295 
nationally representative sample of British children at age 7 years, children from FA treated mothers 296 
scored higher in verbal IQ, general language and full scale IQ.  297 
Apart from its well established role in preventing NTD in very early pregnancy, folate is known 298 
to have other essential roles throughout pregnancy, with impacts in early life and beyond. Folate after 299 
the first trimester of pregnancy is likely to be essential for the developing brain as areas such as the 300 
hippocampus, striatum, auditory and visual cortices are undergoing rapid growth to become 301 
functionally active at this time [33]. There is evidence that children of mothers diagnosed in late 302 
pregnancy with megaloblastic anemia (owing to severe folate deficiency) had abnormal 303 
neurodevelopment and lower intellectual abilities [4]. Likewise, previous studies reported reduced 304 
psychomotor and cognitive ability, or hyperactivity and peer problems, in children of mothers with 305 
with low biomarker folate status at preconception or at the 14th  gestational week of pregnancy [34, 306 
35]. Other studies have linked higher maternal folate status or self-reported FA use in early pregnancy 307 
with improved cognitive performance [6–9] and behavior [16, 17] or reduced risk of severe language 308 
delay [7] in children. Despite differences in study design, timing of maternal sampling during 309 
pregnancy and the tests used to assess cognition, the current findings are in broad agreement with the 310 
aforementioned studies. The majority of previous studies have however relied on records of pregnancy 311 
usage of FA supplements as reported by mothers, and have predominantly focused on the first trimester 312 
of pregnancy where official recommendations for FA supplementation to prevent NTD are in place 313 
worldwide.  In contrast to most previous studies, our study focused on the effects of FA after the period 314 
recommended for NTD prevention (but in women who had taken FA in the first trimester, as per the 315 
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original FASSTT study design), and the findings now provide convincing evidence that better folate 316 
status throughout pregnancy may lead to improved cognitive health outcomes in childhood.  317 
The wider public health relevance of our findings is suggested by the supporting data from 318 
comparison of the cognitive performance of the FASSTT Offspring trial participants with that of a 319 
nationally representative sample of British children of the same age [32]. When compared with British 320 
children at age 7 years, WPPSI-III scores for verbal IQ, general language and full scale IQ were each 321 
higher in children from FA treated mothers. Furthermore, the consistency of our results in relation to 322 
cognitive function as measured at 3 years and at 7 years, despite the use of different assessment tools 323 
at these time points (and smaller sample at 3 years), strengthens our findings.  At both time points, 324 
greater proportions of children from folic acid treated mothers compared with placebo achieved 325 
cognitive scores above the median value for same-sex children at that age. The cognitive domain of 326 
the BSITD-III and the word reasoning test of the WPPSI-III tool measure similar aspects of the brain 327 
including verbal comprehension, concept formation and sensorimotor skills. Our results therefore 328 
indicate that the effect of maternal folate may be specific to the verbal domain and not across the broad 329 
range of cognition assessed at 7 years, or across developmental domains other than cognitive 330 
performance assessed at 3 years. Our findings on cognition are important, not only because 331 
achievement of full cognitive potential of every child is considered paramount for future academic 332 
attainment, but also because evidence suggests that higher intelligence in childhood is a prerequisite 333 
for better cognitive reserves in adulthood that could in turn help to delay cognitive decline in later life 334 
[36–38].  335 
The biological mechanisms explaining our findings are not clear. They are likely however to 336 
relate to the role of folate within one-carbon metabolism, and specifically folate-mediated alterations 337 
in methylation which would result in differential expression of proteins related to production of 338 
neurotransmitters, myelination or synaptic formation in the central nervous system [39, 40]. The 339 
developing brain is particularly vulnerable to these folate-dependent reactions and thus low folate 340 
during pregnancy could impair optimal brain development. Furthermore, epigenetic modifications in 341 
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utero can affect offspring health in later life, with emerging evidence showing that maternal folate can 342 
exert epigenetic effects in pregnancy via DNA methylation which could in turn underlie fetal 343 
programming and fetal brain development [40–42]. We previously reported folate-mediated epigenetic 344 
changes in genes related to brain development and function in the current FASSTT Offspring cohort 345 
when they were newborns [43, 44], and this potentially offers a plausible biological basis to link 346 
maternal folate during pregnancy with the cognitive effects in childhood found in this study. In this 347 
regard however the question of optimal FA dose for beneficial effects is somewhat unclear. The 348 
presence of plasma unmetabolized FA is reported to arise from higher dose FA supplements in 349 
pregnant and nonpregnant women [45], however, it remains to be established whether there are any 350 
associated adverse metabolic or clinical impacts.  One recent prospective cohort study (n= 2213) 351 
showed that one year old children born to mothers reporting to consume FA doses of 5000µg/d or 352 
greater had lower psychomotor development compared to those of mothers who consumed doses of  353 
400-1000µg/d [45], whereas another study observed beneficial effects on neurodevelopment in 18 354 
month old children of 5000µg/d FA taken in early pregnancy compared with no supplementation [8]. 355 
Therefore, the effects of exposure to high dose FA in pregnancy on outcomes in the offspring are 356 
unclear and require further investigation.  In the meantime, given the uncertainty regarding long term 357 
effects of exposure to high dose FA, it seems prudent to recommend doses no higher than those 358 
demonstrated here in later pregnancy, and for NTD prevention in early pregnancy, as being beneficial 359 
with no known harmful effect [46, 47].  360 
A number of factors contribute to the strength of this study. The study design involving the 361 
follow-up of children from participants in an RCT in pregnancy [22] enabled us to demonstrate a 362 
causative link between maternal FA supplementation and subsequent cognition in the child.  Maternal 363 
and newborn responses to FA intervention were measured by RBC folate, which is unaffected by recent 364 
intake and widely considered to be the best biomarker of long term folate status [48]. The use of 365 
internationally recognized tools to measure cognitive performance in children is also a strength, and 366 
enables the results from this maternal intervention with folic acid to be placed in a wider public health 367 
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context for consideration along with findings from other antenatal or child interventions in relation to 368 
cognition in children [49, 50]. The main study outcomes in children sampled at 7 years are supported 369 
by the pilot data from the same children sampled at 3 years, also showing a beneficial effect of maternal 370 
FA on child cognition. Furthermore, the two sampling time-points provided the opportunity to track 371 
cognitive development into childhood and the broad agreement in results at 3 and 7 years contributes 372 
some degree of internal validation to our findings. In addition, in our analysis we controlled for 373 
common confounders including maternal age and education attainment, child’s sex, birth weight and 374 
breastfeeding, previously reported to be strongly associated with child neurodevelopment [28–31]. 375 
This study was however not without limitations, the most significant of which was the relatively small 376 
sample size. Of 119 participants in the original FASSTT trial, 70 (59%) of the mother-child pairs 377 
completed the FASSTT Offspring Trial at 7 years; of these, 34 children were also sampled at 3 years 378 
and provided pilot data in relation to child cognition. Although we made every effort to maximize the 379 
participation rate from the original FASSTT trial, our final sample may have lacked sufficient 380 
statistical power to detect small effects in some test components of the WPPSI-III test. In addition, the 381 
sample may not be representative of children generally, in terms of ethnicity and socioeconomic status, 382 
and therefore the results require confirmation in other populations. Future work in this area would be 383 
much enhanced by combining cognitive tests as used in the current study with non-invasive brain 384 
imaging or novel brain mapping techniques, as previously applied to study the effects of nutritional 385 
interventions in pregnancy on brain health outcomes in the child [51, 52]. 386 
 387 
Conclusions 388 
In summary, the current findings provide the first randomized trial evidence that continued FA 389 
supplementation of mothers through the second and third trimesters of pregnancy can influence the 390 
cognitive performance of their children up to 7 years of age.  The results show that there are benefits 391 
for the child of continuing maternal use of FA throughout pregnancy, whereas current 392 
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recommendations in most countries worldwide advise mothers to take FA supplements from before 393 
conceiving until the end of the 12th gestational week only. If confirmed by further randomized trials 394 
in pregnancy with follow-up in childhood, these findings could have important impacts in informing 395 
future policy and practice in relation to FA recommendations in pregnancy.  396 
 397 
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